<?phpxml version="1.0" encoding="utf-8"?>
<rss version="2.0" 
xmlns:content="http://purl.org/rss/1.0/modules/content/"
xmlns:wfw="http://wellformedweb.org/CommentAPI/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
>
<channel>
<title>The Meetingpoint at Slavyanski.net / phone7taxi / Upvoted</title>
<link>https://slavyanski.net/sb2020</link>
<description>Your Source for Social News and Networking</description>
<pubDate>Fri, 28 Aug 2020 05:36:19 +0000</pubDate>
<language>en</language>
<item>
	<title><![CDATA[Onstrated since all of the ABP 501 lots fell within the quality]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=onstrated-since-all-of-the-abp-501-lots-fell-within-the-quality-3</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=onstrated-since-all-of-the-abp-501-lots-fell-within-the-quality-3"><![CDATA[Onstrated since all of the ABP 501 lots fell within the quality]]></source>
	<description><![CDATA[Onstrated since all of the ABP 501 lots fell within the quality range established based on the adalimumab (US) lots tested. Another mechanism for inducing cell death is the induction of CDC in cells expressing mbTNFa. A comparison of the CDC activity of ABP 501 to that of adalimumab (US) and adalimumab (EU) using MT-3 cells as target cells was conducted. Mean (three independent experiments) percen ]]></description>
	<pubDate>Fri, 28 Aug 2020 05:36:19 +0000</pubDate>
	<author>phone7taxi</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=onstrated-since-all-of-the-abp-501-lots-fell-within-the-quality-3</guid>
</item>

<item>
	<title><![CDATA[Onstrated since all of the ABP 501 lots fell within the quality]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=onstrated-since-all-of-the-abp-501-lots-fell-within-the-quality-5</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=onstrated-since-all-of-the-abp-501-lots-fell-within-the-quality-5"><![CDATA[Onstrated since all of the ABP 501 lots fell within the quality]]></source>
	<description><![CDATA[Onstrated since all of the ABP 501 lots fell within the quality range established based on the adalimumab (US) lots tested. Another mechanism for inducing cell death is the induction of CDC in cells expressing mbTNFa. A comparison of the CDC activity of ABP 501 to that of adalimumab (US) and adalimumab (EU) using MT-3 cells as target cells was conducted. Mean (three independent experiments) percen ]]></description>
	<pubDate>Fri, 28 Aug 2020 04:55:47 +0000</pubDate>
	<author>phone7taxi</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=onstrated-since-all-of-the-abp-501-lots-fell-within-the-quality-5</guid>
</item>

<item>
	<title><![CDATA[Onstrated since all of the ABP 501 lots fell within the quality]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=onstrated-since-all-of-the-abp-501-lots-fell-within-the-quality-3</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=onstrated-since-all-of-the-abp-501-lots-fell-within-the-quality-3"><![CDATA[Onstrated since all of the ABP 501 lots fell within the quality]]></source>
	<description><![CDATA[Onstrated since all of the ABP 501 lots fell within the quality range established based on the adalimumab (US) lots tested. Another mechanism for inducing cell death is the induction of CDC in cells expressing mbTNFa. A comparison of the CDC activity of ABP 501 to that of adalimumab (US) and adalimumab (EU) using MT-3 cells as target cells was conducted. Mean (three independent experiments) percen ]]></description>
	<pubDate>Thu, 27 Aug 2020 08:40:02 +0000</pubDate>
	<author>phone7taxi</author>
	<category></category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=onstrated-since-all-of-the-abp-501-lots-fell-within-the-quality-3</guid>
</item>

<item>
	<title><![CDATA[Onstrated since all of the ABP 501 lots fell within the quality]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=onstrated-since-all-of-the-abp-501-lots-fell-within-the-quality-9</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=onstrated-since-all-of-the-abp-501-lots-fell-within-the-quality-9"><![CDATA[Onstrated since all of the ABP 501 lots fell within the quality]]></source>
	<description><![CDATA[Onstrated since all of the ABP 501 lots fell within the quality range established based on the adalimumab (US) lots tested. Another mechanism for inducing cell death is the induction of CDC in cells expressing mbTNFa. A comparison of the CDC activity of ABP 501 to that of adalimumab (US) and adalimumab (EU) using MT-3 cells as target cells was conducted. Mean (three independent experiments) percen ]]></description>
	<pubDate>Thu, 27 Aug 2020 07:29:54 +0000</pubDate>
	<author>phone7taxi</author>
	<category></category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=onstrated-since-all-of-the-abp-501-lots-fell-within-the-quality-9</guid>
</item>

<item>
	<title><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-2</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-2"><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity]]></source>
	<description><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity to clinical efficacy is unclear, it is important to characterize all activities of the candidate mAb, especially those that can be affected by differences in post-translational modifications, such as glycosylation. The ability of ABP 501 to induce ADCC was assessed using MT-3 cells as target cells, and NK-92M1 cells s ]]></description>
	<pubDate>Wed, 26 Aug 2020 05:30:52 +0000</pubDate>
	<author>phone7taxi</author>
	<category></category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-2</guid>
</item>

<item>
	<title><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-7</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-7"><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity]]></source>
	<description><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity to clinical efficacy is unclear, it is important to characterize all activities of the candidate mAb, especially those that can be affected by differences in post-translational modifications, such as glycosylation. The ability of ABP 501 to induce ADCC was assessed using MT-3 cells as target cells, and NK-92M1 cells s ]]></description>
	<pubDate>Wed, 26 Aug 2020 05:29:43 +0000</pubDate>
	<author>phone7taxi</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-7</guid>
</item>

<item>
	<title><![CDATA[T assays were conducted, and the mean percent relative activity is]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-1</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-1"><![CDATA[T assays were conducted, and the mean percent relative activity is]]></source>
	<description><![CDATA[T assays were conducted, and the mean percent relative activity is reported (see text). A dose response from a single assay of the three is presented here as representative data. e Representative nonconstrained dose?response curves of ABP 501 (red), adalimumab (US) (black), and adalimumab (EU) (blue) showing binding to FcRn. Each point is a mean of three replicates ?standard deviation. Adalimumab  ]]></description>
	<pubDate>Wed, 26 Aug 2020 04:53:21 +0000</pubDate>
	<author>phone7taxi</author>
	<category></category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-1</guid>
</item>

<item>
	<title><![CDATA[T assays were conducted, and the mean percent relative activity is]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-6</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-6"><![CDATA[T assays were conducted, and the mean percent relative activity is]]></source>
	<description><![CDATA[T assays were conducted, and the mean percent relative activity is reported (see text). A dose response from a single assay of the three is presented here as representative data. e Representative nonconstrained dose?response curves of ABP 501 (red), adalimumab (US) (black), and adalimumab (EU) (blue) showing binding to FcRn. Each point is a mean of three replicates ?standard deviation. Adalimumab  ]]></description>
	<pubDate>Wed, 26 Aug 2020 04:52:46 +0000</pubDate>
	<author>phone7taxi</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-6</guid>
</item>

<item>
	<title><![CDATA[Een shown to be similar to adalimumab with respect to binding]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=een-shown-to-be-similar-to-adalimumab-with-respect-to-binding-3</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=een-shown-to-be-similar-to-adalimumab-with-respect-to-binding-3"><![CDATA[Een shown to be similar to adalimumab with respect to binding]]></source>
	<description><![CDATA[Een shown to be similar to adalimumab with respect to binding to a panel of Fc receptors, including FccRIa, FccRIIa, FccRIIIa (158V) (with and without TNFa), and FccRIIIa (158F). Importantly, effector function activation (ADCC and CDC) was also demonstrated to be similar between ABP 501 and adalimumab using highly sensitive methods. The ADCC and CDC methods have been demonstrated to be sensitive t ]]></description>
	<pubDate>Thu, 20 Aug 2020 05:28:10 +0000</pubDate>
	<author>phone7taxi</author>
	<category></category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=een-shown-to-be-similar-to-adalimumab-with-respect-to-binding-3</guid>
</item>

<item>
	<title><![CDATA[Een shown to be similar to adalimumab with respect to binding]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=een-shown-to-be-similar-to-adalimumab-with-respect-to-binding-5</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=een-shown-to-be-similar-to-adalimumab-with-respect-to-binding-5"><![CDATA[Een shown to be similar to adalimumab with respect to binding]]></source>
	<description><![CDATA[Een shown to be similar to adalimumab with respect to binding to a panel of Fc receptors, including FccRIa, FccRIIa, FccRIIIa (158V) (with and without TNFa), and FccRIIIa (158F). Importantly, effector function activation (ADCC and CDC) was also demonstrated to be similar between ABP 501 and adalimumab using highly sensitive methods. The ADCC and CDC methods have been demonstrated to be sensitive t ]]></description>
	<pubDate>Thu, 20 Aug 2020 05:27:46 +0000</pubDate>
	<author>phone7taxi</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=een-shown-to-be-similar-to-adalimumab-with-respect-to-binding-5</guid>
</item>

<item>
	<title><![CDATA[Assessment of the bioactivity of adalimumab should include assessment of multiple]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=assessment-of-the-bioactivity-of-adalimumab-should-include-assessment-of-multiple-3</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=assessment-of-the-bioactivity-of-adalimumab-should-include-assessment-of-multiple-3"><![CDATA[Assessment of the bioactivity of adalimumab should include assessment of multiple]]></source>
	<description><![CDATA[Assessment of the bioactivity of adalimumab should include assessment of multiple in vitro endpoints (NFjB-dependent and NFjB-independent) and should include binding to both soluble and transmembrane TNFa. ABP 501 has been shown to be similar to adalimumab in its ability to neutralize TNFa-induced caspase activation, chemokine production, and cytotoxicity, functions inclusive of both NFjB-dependen ]]></description>
	<pubDate>Thu, 20 Aug 2020 04:27:14 +0000</pubDate>
	<author>phone7taxi</author>
	<category></category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=assessment-of-the-bioactivity-of-adalimumab-should-include-assessment-of-multiple-3</guid>
</item>

<item>
	<title><![CDATA[T assays were conducted, and the mean percent relative activity is]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-7</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-7"><![CDATA[T assays were conducted, and the mean percent relative activity is]]></source>
	<description><![CDATA[T assays were conducted, and the mean percent relative activity is reported (see text). A dose response from a single assay of the three is presented here as representative data. e Representative nonconstrained dose?response curves of ABP 501 (red), adalimumab (US) (black), and adalimumab (EU) (blue) showing binding to FcRn. Each point is a mean of three replicates ?standard deviation. Adalimumab  ]]></description>
	<pubDate>Tue, 18 Aug 2020 20:35:54 +0000</pubDate>
	<author>phone7taxi</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-7</guid>
</item>

<item>
	<title><![CDATA[T assays were conducted, and the mean percent relative activity is]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-1</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-1"><![CDATA[T assays were conducted, and the mean percent relative activity is]]></source>
	<description><![CDATA[T assays were conducted, and the mean percent relative activity is reported (see text). A dose response from a single assay of the three is presented here as representative data. e Representative nonconstrained dose?response curves of ABP 501 (red), adalimumab (US) (black), and adalimumab (EU) (blue) showing binding to FcRn. Each point is a mean of three replicates ?standard deviation. Adalimumab  ]]></description>
	<pubDate>Tue, 18 Aug 2020 20:35:23 +0000</pubDate>
	<author>phone7taxi</author>
	<category></category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-1</guid>
</item>

<item>
	<title><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-5</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-5"><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity]]></source>
	<description><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity to clinical efficacy is unclear, it is important to characterize all activities of the candidate mAb, especially those that can be affected by differences in post-translational modifications, such as glycosylation. The ability of ABP 501 to induce ADCC was assessed using MT-3 cells as target cells, and NK-92M1 cells s ]]></description>
	<pubDate>Tue, 18 Aug 2020 20:09:29 +0000</pubDate>
	<author>phone7taxi</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-5</guid>
</item>

<item>
	<title><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-8</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-8"><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity]]></source>
	<description><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity to clinical efficacy is unclear, it is important to characterize all activities of the candidate mAb, especially those that can be affected by differences in post-translational modifications, such as glycosylation. The ability of ABP 501 to induce ADCC was assessed using MT-3 cells as target cells, and NK-92M1 cells s ]]></description>
	<pubDate>Tue, 18 Aug 2020 20:08:59 +0000</pubDate>
	<author>phone7taxi</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-8</guid>
</item>

<item>
	<title><![CDATA[T assays were conducted, and the mean percent relative activity is]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-4</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-4"><![CDATA[T assays were conducted, and the mean percent relative activity is]]></source>
	<description><![CDATA[T assays were conducted, and the mean percent relative activity is reported (see text). A dose response from a single assay of the three is presented here as representative data. e Representative nonconstrained dose?response curves of ABP 501 (red), adalimumab (US) (black), and adalimumab (EU) (blue) showing binding to FcRn. Each point is a mean of three replicates ?standard deviation. Adalimumab  ]]></description>
	<pubDate>Mon, 17 Aug 2020 18:12:17 +0000</pubDate>
	<author>phone7taxi</author>
	<category></category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-4</guid>
</item>

<item>
	<title><![CDATA[Onstrated since all of the ABP 501 lots fell within the quality]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=onstrated-since-all-of-the-abp-501-lots-fell-within-the-quality-7</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=onstrated-since-all-of-the-abp-501-lots-fell-within-the-quality-7"><![CDATA[Onstrated since all of the ABP 501 lots fell within the quality]]></source>
	<description><![CDATA[Onstrated since all of the ABP 501 lots fell within the quality range established based on the adalimumab (US) lots tested. Another mechanism for inducing cell death is the induction of CDC in cells expressing mbTNFa. A comparison of the CDC activity of ABP 501 to that of adalimumab (US) and adalimumab (EU) using MT-3 cells as target cells was conducted. Mean (three independent experiments) percen ]]></description>
	<pubDate>Mon, 17 Aug 2020 17:19:12 +0000</pubDate>
	<author>phone7taxi</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=onstrated-since-all-of-the-abp-501-lots-fell-within-the-quality-7</guid>
</item>

<item>
	<title><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-1</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-1"><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity]]></source>
	<description><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity to clinical efficacy is unclear, it is important to characterize all activities of the candidate mAb, especially those that can be affected by differences in post-translational modifications, such as glycosylation. The ability of ABP 501 to induce ADCC was assessed using MT-3 cells as target cells, and NK-92M1 cells s ]]></description>
	<pubDate>Fri, 14 Aug 2020 18:12:16 +0000</pubDate>
	<author>phone7taxi</author>
	<category></category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-1</guid>
</item>

<item>
	<title><![CDATA[T assays were conducted, and the mean percent relative activity is]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-6</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-6"><![CDATA[T assays were conducted, and the mean percent relative activity is]]></source>
	<description><![CDATA[T assays were conducted, and the mean percent relative activity is reported (see text). A dose response from a single assay of the three is presented here as representative data. e Representative nonconstrained dose?response curves of ABP 501 (red), adalimumab (US) (black), and adalimumab (EU) (blue) showing binding to FcRn. Each point is a mean of three replicates ?standard deviation. Adalimumab  ]]></description>
	<pubDate>Fri, 14 Aug 2020 17:14:52 +0000</pubDate>
	<author>phone7taxi</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-6</guid>
</item>

<item>
	<title><![CDATA[T assays were conducted, and the mean percent relative activity is]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-2</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-2"><![CDATA[T assays were conducted, and the mean percent relative activity is]]></source>
	<description><![CDATA[T assays were conducted, and the mean percent relative activity is reported (see text). A dose response from a single assay of the three is presented here as representative data. e Representative nonconstrained dose?response curves of ABP 501 (red), adalimumab (US) (black), and adalimumab (EU) (blue) showing binding to FcRn. Each point is a mean of three replicates ?standard deviation. Adalimumab  ]]></description>
	<pubDate>Fri, 14 Aug 2020 17:14:17 +0000</pubDate>
	<author>phone7taxi</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-2</guid>
</item>

<item>
	<title><![CDATA[T assays were conducted, and the mean percent relative activity is]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-7</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-7"><![CDATA[T assays were conducted, and the mean percent relative activity is]]></source>
	<description><![CDATA[T assays were conducted, and the mean percent relative activity is reported (see text). A dose response from a single assay of the three is presented here as representative data. e Representative nonconstrained dose?response curves of ABP 501 (red), adalimumab (US) (black), and adalimumab (EU) (blue) showing binding to FcRn. Each point is a mean of three replicates ?standard deviation. Adalimumab  ]]></description>
	<pubDate>Tue, 11 Aug 2020 18:21:10 +0000</pubDate>
	<author>phone7taxi</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-7</guid>
</item>

<item>
	<title><![CDATA[T assays were conducted, and the mean percent relative activity is]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-9</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-9"><![CDATA[T assays were conducted, and the mean percent relative activity is]]></source>
	<description><![CDATA[T assays were conducted, and the mean percent relative activity is reported (see text). A dose response from a single assay of the three is presented here as representative data. e Representative nonconstrained dose?response curves of ABP 501 (red), adalimumab (US) (black), and adalimumab (EU) (blue) showing binding to FcRn. Each point is a mean of three replicates ?standard deviation. Adalimumab  ]]></description>
	<pubDate>Tue, 11 Aug 2020 18:20:39 +0000</pubDate>
	<author>phone7taxi</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-9</guid>
</item>

<item>
	<title><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-3</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-3"><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity]]></source>
	<description><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity to clinical efficacy is unclear, it is important to characterize all activities of the candidate mAb, especially those that can be affected by differences in post-translational modifications, such as glycosylation. The ability of ABP 501 to induce ADCC was assessed using MT-3 cells as target cells, and NK-92M1 cells s ]]></description>
	<pubDate>Fri, 07 Aug 2020 05:28:30 +0000</pubDate>
	<author>phone7taxi</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-3</guid>
</item>

</channel>
</rss>
